TOP2A overexpression as a poor prognostic factor in patients with nasopharyngeal carcinoma

Tumor Biology

Volumn 35, Issue 1, 2014, Pages 179-187

  Lan, Jui ^a   Huang, Hsuan Ying ^a   Lee, Sung Wei ^b   Chen, Tzu Ju ^b   Tai, Hui Chun ^c   Hsu, Han Ping ^b   Chang, Kwang Yu ^d   Li, Chien Feng ^b,d,e,f,g  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

^c CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^e SOUTHERN TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^f KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^g KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Nasopharyngeal carcinoma; Prognosis; TOP2A; Transcriptome

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); TOPOISOMERASE II ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE SPECIFIC SURVIVAL; DISTANT METASTASIS FREE SURVIVAL; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOCAL RECURRENCE FREE SURVIVAL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TUMOR BIOPSY; UPREGULATION; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CLUSTER ANALYSIS; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; YOUNG ADULT;

EID: 84893757904     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1022-6     Document Type: Article

References (36)

1. Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet. 2005;365:2041-54.
2. Fang FM, Tsai WL, Chen HC, Hsu HC, et al. Intensity-modulated or conformal radiotherapy improves the quality of life of patients with nasopharyngeal carcinoma: comparisons of four radiotherapy techniques. Cancer. 2007;109:313-21.
3. Fang FM, Chien CY, Tsai WL, Chen HC, et al. Quality of life and survival outcome for patients with nasopharyngeal carcinoma receiving three-dimensional conformal radiotherapy vs. intensity-modulated radiotherapy - a longitudinal study. Int J Radiat Oncol Biol Phys. 2008;72:356-64.
4. Kwong DL, Pow EH, Sham JS, McMillan AS, et al. Intensity-modulated radiotherapy for early-stage nasopharyngeal carcinoma: a prospective study on disease control and preservation of salivary function. Cancer. 2004;101:1584-93.
5. Tham IW, Lu JJ. Controversies and challenges in the current management of nasopharyngeal cancer. Expert Rev Anticancer Ther. 2010;10:1439-50.
6. Lin JC, Jan JS, Hsu CY, Liang WM, et al. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol. 2003;21:631-7.
7. Wee J, Tan EH, Tai BC, Wong HB, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union Against Cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol. 2005;23:6730-8.
8. Deweese JE, Osheroff N. The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing. Nucleic Acids Res. 2009;37:738-48.
9. Kaplan E, Gunduz U. Expression analysis of top2a, msh2 and mlh1 genes in mcf7 cells at different levels of etoposide resistance. Biomed Pharmacother Biomed pharmacother. 2012;66:29-35.
10. Pritchard KI, Messersmith H, Elavathil L, Trudeau M, et al. Her-2 and topoisomerase II as predictors of response to chemotherapy. J Clin Oncol. 2008;26:736-44.
11. Brase JC, Schmidt M, Fischbach T, Sultmann H, et al. Erbb2 and top2a in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction. Clin Cancer Res. 2010;16:2391-401.
12. Sengupta S, den Boon JA, Chen IH, Newton MA, et al. Genome-wide expression profiling reveals ebv-associated inhibition of mhc class I expression in nasopharyngeal carcinoma. Cancer Res. 2006;66:7999-8006.
13. Bames LEJ, Relchart P, Sidransky D, editors. Pathology and genetics of head and neck tumors. Lyon: IARCP Press; 2005.
14. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual. 7th ed. Heidelberg: Springer; 2010.
15. Goulding H, Pinder S, Cannon P, Pearson D, et al. A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples. Hum Pathol. 1995;26:291-4.
16. Wolden SL, Zelefsky MJ, Kraus DH, Rosenzweig KE, et al. Accelerated concomitant boost radiotherapy and chemotherapy for advanced nasopharyngeal carcinoma. J Clin Oncol. 2001;19:1105-10.
17. Spratt DE, Lee N. Current and emerging treatment options for nasopharyngeal carcinoma. Oncol Targets Ther. 2012;5:297-308.
18. Wendorff TJ, Schmidt BH, Heslop P, Austin CA, et al. The structure of DNA-bound human topoisomerase II alpha: conformational mechanisms for coordinating inter-subunit interactions with DNA cleavage. J Mol Biol. 2012;424:109-24.
19. Di Leo A, Gancberg D, Larsimont D, Tanner M, et al. Her-2 amplification and topoisomerase II alpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res. 2002;8:1107-16.
20. Konecny GE, Pauletti G, Untch M, Wang HJ, et al. Association between her2, top2a, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer. Breast Cancer Res Treat. 2010;120:481-9.
21. Wong N, Yeo W, Wong WL, Wong NL, et al. Top2a overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance. Int J Cancer. 2009;124:644-52.
22. Mirski SE, Sparks KE, Yu Q, Lang AJ, et al. A truncated cytoplasmic topoisomerase II alpha in a drug-resistant lung cancer cell line is encoded by a top2a allele with a partial deletion of exon 34. Int J Cancer. 2000;85:534-9.
23. McLeod HL, Douglas F, Oates M, Symonds RP, et al. Topoisomerase I and II activity in human breast, cervix, lung and colon cancer. Int J Cancer. 1994;59:607-11.
24. Fountzilas G, Valavanis C, Kotoula V, Eleftheraki AG, et al. Her2 and top2a in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy. J Transl Med. 2012;10:10.
25. Kanta SY, Yamane T, Dobashi Y, Mitsui F, et al. Topoisomerase II alpha gene amplification in gastric carcinomas: correlation with the her2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study. Hum Pathol. 2006;37:1333-43.
26. Romero A, Martin M, Cheang MC, Lopez Garcia-Asenjo JA, et al. Assessment of topoisomerase II alpha status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization. Am J Pathol. 2011;178:1453-60.
27. Mueller RE, Parkes RK, Andrulis I, O'Malley FP. Amplification of the top2a gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples. Genes Chromosome Cancer. 2004;39:288-97.
28. Crago AM, Singer S. Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma. Curr Opin Oncol. 2011;23:373-8.
29. Gobble RM, Qin LX, Brill ER, Angeles CV, et al. Expression profiling of liposarcoma yields a multigene predictor of patient outcome and identifies genes that contribute to liposarcomagenesis. Cancer Res. 2011;71:2697-705.
30. da Cunha IW, De Brot L, Carvalho KC, Rocha RM, et al. Prognostication of soft tissue sarcomas based on chromosome 17q gene and protein status: evaluation of top2a, her-2/neu, and survivin. Ann Surg Oncol. 2012;19:1790-9.
31. Fornari FA, Randolph JK, Yalowich JC, Ritke MK, et al. Interference by doxorubicin with DNA unwinding in mcf-7 breast tumor cells. Mol Pharmacol. 1994;45:649-56.
32. Hande KR. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer. 1998;34:1514-21.
33. Schindlbeck C, Mayr D, Olivier C, Rack B, et al. Topoisomerase II alpha expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer. J Cancer Res Clin Oncol. 2010;136:1029-37.
34. Nikolenyi A, Sukosd F, Kaizer L, Csorgo E, et al. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer. Oncology. 2011;80:269-77.
35. Toyoda E, Kagaya S, Cowell IG, Kurosawa A, et al. Nk314, a topoisomerase II inhibitor that specifically targets the alpha isoform. J Biol Chem. 2008;283:23711-20.
36. Onda T, Toyoda E, Miyazaki O, Seno C, et al. Nk314, a novel topoisomerase II inhibitor, induces rapid DNA double-strand breaks and exhibits superior antitumor effects against tumors resistant to other topoisomerase II inhibitors. Cancer Lett. 2008;259:99-110.